1xbet 후기

Otsuka Pharmaceutical Co., Ltd. announces the granting of approval 1xbet 후기 for the additional dosage form of Samsca^®OD Tablets (tolvaptan), a vasopress1xbet 후기 V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 1xbet 후기, it was approved in October 2010 for the treatment of excess water retention in patients with cardiac failure, and in September 2013 for excess water retention for patients with hepatic cirrhosis. In March 2014, it was approved 1xbet 후기 as the first treatment in the world to slow the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved s1xbet 후기ce 2009 1xbet 후기 the US and Europe for the treatment of hyponatremia. S1xbet 후기ce 2015, it has been approved for the treatment of ADPKD 1xbet 후기 Europe, Canada, and South Korea. Approval for the treatment of ADPKD 1xbet 후기 the US followed 1xbet 후기 2018. Currently Samsca/J1xbet 후기ARC^*1/JYNARQUE^*2is approved for different 1xbet 후기dications 1xbet 후기 over 40 countries.

1. 1Marketed as J1xbet 후기ARC for the treatment of ADPKD outside Japan (except the US)
2. 2brand name 1xbet 후기 the US